Catalog Number:  C22-101-13
Source:  Escherichia coli.
Molecular Weight:  Approximately12.5 kDa, a single non-glycosylated polypeptide chain containing 112 amino acids.
Quantity:  2μg/10μg/1000μg
AA Sequence:  GPVPPSTALR ELIEELVNIT QNQKAPLCNG SMVWSINLTA GMYCAALESL INVSGCSAIE
 KTQRMLSGFC PHKVSAGQFS SLHVRDTKIE VAQFVKDLLL HLKKLFREGR FN
Purity:  >96% by SDS-PAGE and HPLC analyses.
Biological Activity:  Fully biologically active when compared to standard. The ED50 determined by a cell proliferation
 assay using human TF-1 cells is less than 1 ng/ml, corresponding to a specific activity of＞ 1.0 × 106 IU/mg.
Physical Appearance:  Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation:  Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH 7.4.
Endotoxin:  Less than 1EU/μg of rHuIL-13 as determined by LAL method.
Reconstitution:  We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the
 bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a
 concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and
 stored at <-20°C. Further dilutions should be made in appropriate buffered solutions.
Storage:  This lyophilized preparation is stable at 2-8°C, but should be kept at -20°C for long term storage,
 preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For
 maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to
 -70°C. Avoid repeated freeze/thaw cycles.
Usage:  This material is offered by Shanghai Corning Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

Human Interleukin-13
Interleukin-13 (IL-13) is an immunoregulatory cytokine produced primarily by activated Th2 cells, and also by mast cells and
NK cells. Targeted deletion of IL-13 in mice resulted in impaired Th2 cell development and indicated an important role for IL-13
in the expulsion of gastrointestinal parasites. IL-13 exerts anti-inflammatory effects on monocytes and macrophages and it
inhibits the expression of inflammatory cytokines such as IL-1beta, TNF-alpha, IL-6 and IL-8. IL-13 has also been shown to
enhance B cell proliferation and to induce isotype switching resulting in increased production of IgE. Blocking of IL-13 activity
inhibits the pathophysiology of asthma. Human and murine IL-13 is cross-species reactive.